Skip to main content
Premium Trial:

Request an Annual Quote

Accelerate Dx Posts Increase in Q2 Revenues, Net Loss

NEW YORK (GenomeWeb) - Accelerate Diagnostics today said that revenues for its second quarter rose 46 percent.

According to a document filed with the US Securities and Exchange Commission, for the three months ended June 30, the Tucson, Arizona-based molecular diagnostics company said that revenues increased to $19,000 from $13,000 a year ago, composed entirely of revenues associated with licensing agreements.

The firm's net loss in the quarter was $12.3 million, or $.27 per share, compared to a net loss of $8.2 million, or $.19 per share, in the prior-year period.

Accelerate Diagnostics' R&D spending rose to $7.1 million, up 56 percent from $4.6 million during the second quarter of 2014, driven by new hires and increased purchases of laboratory and instrument engineering supplies to support R&D. Its SG&A costs rose 38 percent to $4.8 million from $3.4 million, driven by increases in salaries and related expenses as the firm ramped up operations.

Accelerate Diagnostics ended the quarter with $35.2 million in cash and cash equivalents.

In mid-day trade Monday on the Nasdaq, shares of Accelerate Dx were down 8 percent at $25.65.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.